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Abstract 
Purpose: To observe the clinical effects of sirolimus (SRL) immunosuppressive therapy in patients with 
progressively increasing levels of serum creatinine (Scr) after renal transplant.  
Methods: In total, 180 patients whose Scr levels had been rising after renal transplant were given an 
oral calcineurin inhibitor (CNI): either cyclosporine A (CsA) or tacrolimus (FK506). All patients were 
treated at People’s Hospital of Zhengzhou, China, between January 2011 and December 2013, and 
were given SRL-based conversion treatment. Scr level and glomerular filtration rate (GFR) were 
observed before and 1, 3, and 6 months after treatment initiation. In addition, liver function, blood 
glucose, blood lipid levels, rejection reaction incidence, and mortality were recorded to evaluate the 
effects of SRL.  
Results: Scr levels were 116.60 ± 30.60 μmol/L and 119.00 ± 24.60 μmol/L, and GFR was 70.00 ± 
19.70 mL/min and 75.90 ± 15.60 mL/min, at 3 and 6 months after treatment, respectively. The 3- and 6-
month Scr and GFR values were statistically different (p < 0.05) compared to pre-treatment levels (Scr: 
144.10 ± 61.70 μmol/L vs and GFR: 59.10 ± 16.20 mL/min. Acute rejection (AR) occurred in 20 patients 
(13.30 %) within 6 months of treatment initiation, but rejection was reversed with conventional 
methylprednisolone therapy. Twenty-one patients (11.70 %) developed lung infections, but all were 
cured. There were no significant differences in liver function before and after treatment.  
Conclusion: SRL-based immunosuppressive therapy is effective in treating patients with increased Scr 
levels after renal transplant.   
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The extensive application of novel 
immunosuppressors has led to a dramatic 
reduction in acute rejection (AR) incidence; 
however, long-term survival after renal transplant 
is still not adequate [1,2]. The key factors 
influencing patient and kidney survival include 
liver and kidney toxicity, diabetes occurrence, 
chronic allograft nephropathy, and malignant 
tumors occurring after transplant [3,4]. 
Calcineurin inhibitors (CNIs) are currently the 
most commonly used immunosuppressors in 
renal transplant patients, and CNI treatment 
significantly improves survival rates after 
transplantation. However, chronic allograft 
nephropathy (CAN) is caused by renal toxicity, 
which can be induced by CNI treatment. The 
occurrence of CAN due to immunosupressor 
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treatment has increased research interest in the 
transplantation field [5]. 
 
Serum creatinine (Scr) levels progressively 
increase after transplantation in kidneys that 
enter the decompensation period after CAN. If 
this decompensation fails to be controlled, 
transplanted kidney function will be lost. 
However, the development of new 
immunosuppressors, such as sirolimus (SRL), 
make it possible to stop CNI treatment [6]. 
Treating renal transplant patients with 
immunosuppressive drugs other than CNIs has 
received more attention in recent years. SRL, a 
new generation of powerful immunosuppressor, 
has less renal toxicity as well as anti-proliferative 
and anti-tumor effect [7]. SRL treatment 
represents a potential alternative to CNIs for 
renal transplant patients. Therefore, the 
prevention of complications and improvement of 
long-term survival rates in renal transplant 
patients has attracted a lot of attention in recent 
years. Currently, researchers are trying to find an 
alternative but equally effective treatment to 
CNIs. In this study, 180 patients who developed 
CAN after renal transplant at Zhengzhou 
People’s Hospital between February 2011 and 
December 2013 were treated with SRL 






In total, 180 patients who developed CAN after 
renal transplant were selected from Zhengzhou 
People’s Hospital between February 2011 and 
December 2013. Of the 180 cases, 120 were 
male and 60 were female, with ages ranging 
from 27 to 49 years (mean, 38.60 ± 2.40 years). 
Conversion treatment started, on average, (46 ± 
10) months after transplantation. Before 
conversion treatment, 103 cases were given 
cyclosporine A (CsA) + mycophenolate mofetil 
(MMF) + prednisone-combined 
immunosuppressive therapy while 77 cases were 
given tacrolimus (FK506) + MMF + prednisone-
combined immunosuppressive therapy. All 
patients gave written informed consent; the study 
has been approved by People’s Hospital of 
Zhengzhou Ethics Committee (approval no. 
QGYZ201503901) and it followed the guidelines 




Patients with the following traits were selected: 
stable transplant kidney function with Scr level 
>140 μmol/L and increased blood pressure and 
proteinuria 6 months after kidney transplant; 
patients with CNI-induced hepatotoxicity or 
abnormal liver function after transplant; patients 
with diabetes or hyperglycemia after transplant 
that was controlled with hypoglycemic drugs or 
insulin; patients who had fibrosis in the transplant 
kidney confirmed by aspiration biopsy; and 
patients who had renal tubule atrophy combined 
with intimal hyperplasia but without AR. Patients 
who could not undergo immunosuppressive 
therapy due to a specific disease or financial 
conditions or who had serum cholesterol over 6 
mmol/L, triacylglycerol over 2 mmol/L, 24-hour 
proteinuria over 0.80 g, peripheral blood 
leucocyte counts less than 3.5 × 109/L, and blood 





SRL treatment began upon cessation of CNI 
treatment. Patients were given 3 - 6 mg/d SRL 
on the first day, and then 1 - 2 mg/d for 5 - 7 
days. After 7 days, blood SRL concentration was 
maintained at 5 - 15 ng/mL by taking SRL orally. 
SRL concentration was controlled within the 
therapeutic window range. The dosage of other 




Scr level and glomerular filtration rate (GFR) 
were detected before, and 1, 3, and 6 months 
after treatment initiation. AR incidence, infection 
rate, renal allograft dysfunction rate, and death 
rate were observed for 6 months after treatment. 
Liver function, blood glucose, blood parameters, 
and 24-hour proteinuria were measured before 





SPSS 19.0 software was used to analyze the 
data. All values are expressed as mean ± 
standard deviation (SD). Comparison of means 
was performed using a non-paired t-test. 
Differences were considered statistically 




Analysis of AR and infection after conversion 
treatment 
 
Of the 180 cases, 24 (13.30 %) experienced mild 
AR (level IA - IB) within 6 months of SRL 
treatment initiation, but all cases were 
successfully treated with cortical hormones. After 
AR treatment, all patients had stable renal 
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function and no repeat AR. Of the 24 AR cases, 
12 had no more AR incidents 6 months after 
cessation of cortical hormone treatment. No 
deaths or cases of kidney dysfunction were 
observed in the 6 months after SRL treatment 
initiation. Twenty-one patients (11.70 %) 
developed lung infections, including 12 cases of 
cytomegalovirus (CMV) infection (accounting for 
57.10 % among infection cases), 6 cases of 
bacterial infection (28.60 %), and 3 cases of 
fungal infection (14.30 %); however, all patients 
were cured by traditional anti-infection 
treatments. 
 
Changes in Scr and GFR before and after 
conversion treatment 
 
Scr levels decreased and GFR increased in the 
first 6 months of treatment, with significant 
differences beginning in the 3rd month (p < 0.05) 
(Figure 1). 
 
Changes in liver function and blood glucose 
 
There were no differences in liver function before 
and after treatment (p > 0.05). Blood glucose 
levels were normalized after treatment, and this 




Of the 180 cases, 75 cases (41.70 %) had 
increased blood lipid levels after SRL treatment, 
with 24 cases of increased triglyceride 
(accounting for 32 % among all cases with 
increase blood lipids), and 51 cases of increased 
cholesterol (68 %); In addition, 9 patients (5 %) 
had decreased leukocyte counts, 6 had (3.30 %) 
decreased platelet counts, and 60 (33.30 %) had 
increased urine protein. Except for blood platelet 
and leukocyte counts, the other measures 
described here were significantly different 3 and 





Immunosuppressors are an indispensable tool 
for organ transplantation success. Individual 
differences and an insufficient understanding of 
the immune system can affect the development 
of effective immunosuppressive drugs [9]. 
 
 
           Figure 1: Scr and GFR levels 
 
Table 1: Liver function and blood glucose changes before and after conversion treatment (mean ± SD) 
 
Time point ALT (IU/L) AST (IU/L) TBIL (μmol/L) Glu (mmol/L) 
Before conversion treatment 46.84±10.04 35.78±12.15 22.70±9.30 9.00±0.90 
1 month after conversion 
treatment 41.80±18.37 37.83±17.28 25.30±5.80 6.70±0.80
* 
3 months after conversion 
treatment 50.15±13.35 27.00±19.10 20.30±5.20 5.90±1.10
* 
6 months after conversion 
treatment 43.13±11.70 26.00±15.20 19.20±4.60 5.60±0.70
* 
*P < 0.05 compared to pre-conversion treatment; ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; TBIL: total bilirubin; Glu: blood glucose 
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    Table 2: Comparison of adverse reactions at different time points after SRL treatment initiation 
 
Parameter Before  After conversion treatment 1 month 3 months 6 months 
Triglyceride  (mmol/L) 1.86±0.87 2.16±0.96 2.18±0.90* 2.23±0.89* 
Cholesterol  (mmol/L) 5.12±1.08 5.81±1.25 6.17±1.21* 6.21±1.29* 
Leukocyte (×109/L) 8.87±2.99 8.28±2.56 8.06±2.41 8.08±2.47 
Blood platelet (×109/L) 224.10±61.70 223.80±65.90 217.10±59.60 214.10±62.80 
Urine protein (g/24h) 0.36±0.24 0.38±0.19 0.50±0.27* 0.52±0.25* 
     * P < 0.05 compared to prior conversion treatment 
 
CNI treatment is known to have a stable and 
anti-rejection effect on transplant patients; 
however, renal toxicity induced by long-term CNI 
treatment is a significant issue and occurs in the 
majority of CNI-treated patients. Nankivell et al 
[10] found that 68 % of patients with CNI-induced 
renal toxicity had CAN 1 year after transplant; 62 
% of patients treated with FK506 developed CAN 
2 years after transplant; and 72 % of patients 
treated with CsA developed CAN 2 years after 
transplant. Therefore, reducing or avoiding CNI 
treatment can lower the incidence of CAN and 
improve long-term survival rates in transplant 
patients, as well as increasing transplant organ 
survival. 
  
SRL, a new generation of immunosuppressor, is 
characterized by reduced renal toxicity. SRL is 
mainly metabolized in the liver and 
gastrointestinal tract through the cytochrome 
P450 system, and over 91 % of the metabolite 
product is expelled through the gastrointestinal 
tract, and a further 2 % is expelled through the 
skin [11,12]. SRL prevents the transition from G1 
phase to S phase in T lymphocytes, and can 
therefore prevent interleukin-2 (IL-2) receptor 
binding and Tc and Td cell sensitization [13]. In 
addition, previous studies have shown that SRL 
also has anti-proliferative and anti-tumor effects 
[14,15] SRL can be an alternative treatment to 
CNI for patients who develop tumors or CAN 
after rental transplant.. In this study, Scr levels 
decreased and GFR increased in the 6 month 
period after SRL treatment initiation. Overall, 
SRL was effective at treating CAN. 
  
Risk is inevitable when using a new 
immunosuppressor for conversion treatment. 
First, the occurrence of AR and excessive 
immunosuppression should be noted during 
treatment [16,17]. In this study, 24 cases 
experienced AR within 6 months of SRL 
treatment initiation, and this appeared to 
correlate with the withdrawal of FK506, unstable 
blood SRL concentration, absorption differences, 
and liver metabolism [18]. Lung infections usually 
occur when immunosuppression is excessive. Of 
the 180 cases, 21 developed lung infections 
within 6 months of conversion treatment 
initiation; however, all recovered after traditional 
anti-infection treatment and SRL dosage 
adjustment. This indicates that insufficient and 
excessive immunosuppression can be avoided 
during conversion treatment with SRL. 
 
In addition, there were no remarkable differences 
in liver function after conversion therapy 
initiation, and blood glucose levels were 
normalized, suggesting that SRL had little 
influence on blood glucose levels. Adverse 
reactions included hyperlipidemia, proteinuria, 
and myelosuppression. In this study, 75 of 180 
cases (41.70 %) had increased blood lipid levels 
after conversion treatment, with significant 
differences beginning 3 months after treatment 
initiation.  
 
The increased lipid levels were found to be dose-
dependent; therefore, blood lipid levels could be 
managed by decreasing the dose of SRL. Forty 
patients (33.30 %) experienced increased 
proteinuria, with significant differences beginning 
3 months after treatment initiation. Although all 
patients continued SRL treatment despite 
proteinuria and its unknown mechanism of 
action, this may be a concern for the future 




The findings show that renal function improved 
after conversion treatment, indicating that SRL 
was more effective than FK506. SRL-based 
immunosuppressive therapy is effective and safe 
for treating FK506-induced Scr increases; 
however, the optimal dose and treatment plan for 
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